#United States #New York #Liquid Biopsy #Rarecells Inc. #Dr. Neil Kurtz

Rarecells Inc. Welcomes Dr. Neil Kurtz as New Board Member

Rarecells Inc., recognized for its advancements in liquid biopsy technology, has announced the significant appointment of Dr. Neil Kurtz to its Board of Directors. With an illustrious career spanning four decades in the healthcare sector, Dr. Kurtz brings a wealth of knowledge and expertise that is expected to have a profound impact on the company’s future.

Dr. Kurtz is an established entrepreneur and executive, having founded several successful enterprises, including Medidata Systems and Worldwide Clinical Trials. Under his leadership, these companies reportedly generated over $8 billion in total value for investors. His extensive career also includes roles as CEO for various public and private organizations, showcasing his command in navigating complex business landscapes.

Most notably, he has held prestigious positions within significant healthcare organizations, including serving as President and CEO of Golden Living, one of the largest providers of diversified healthcare services in the U.S. His experience in executive leadership, coupled with substantial insights into pharmaceutical and medical diagnostics, makes him a desirable addition to Rarecells’ Board.

Dr. Patrizia Paterlini, CEO of Rarecells Inc., expressed her enthusiasm about this development, stating, "We are delighted to welcome Dr. Kurtz to our Board of Directors. His extensive expertise in diagnostics, finance, and scientific research will be invaluable as we continue to develop and commercialize our innovative liquid biopsy technology for early cancer detection."

This strategic appointment aims to fortify Rarecells’ commitment to its mission: delivering unparalleled access to intact circulating tumor cells and their CTC-DNA for downstream analysis. As the company ventures deeper into the realm of precision oncology, Dr. Kurtz’s multifaceted background will undoubtedly aid in guiding the company towards its objectives.

Reflecting on his new role, Dr. Kurtz stated, "I am honored to join the already exceptional Board of Directors at Rarecells. I believe that through its ISET technology, the company holds the potential to revolutionize cancer diagnostics and personalized treatment. I look forward to contributing my insights gained from my industry experience to propel Rarecells’ growth and success in this critical field."

Currently, Dr. Kurtz is the fifth member of Rarecells’ Board. He joins an esteemed group of individuals including Dr. Patrizia Paterlini, Neil Gunn, PhD, Christian Brechot, MD, PhD, and Thierry de Marignac, all of whom bring their own vast experience and specialized knowledge to the team.

Founded in 2012, Rarecells Inc. is at the forefront of developing innovative non-invasive tests for the early diagnosis of cancer. The company employs advanced AI-based methods for detecting circulating tumor cells (CTCs) and CTC-DNA. It has its headquarters in New York while also maintaining offices and laboratories in Paris, positioning itself as a major player in the global oncological diagnostic landscape.

As Rarecells continues to pursue its mission of enhancing cancer diagnostics, the integration of Dr. Kurtz into the leadership team is anticipated to catalyze significant advancements and drive innovative solutions in cancer detection and patient care. The company expects this strategic appointment to further enhance its operations and effectiveness in addressing the unmet needs of patients worldwide, thereby empowering lives through cutting-edge technology.

For more information about Rarecells Inc. and its initiatives, please visit www.rarecells.com.